https://scholars.lib.ntu.edu.tw/handle/123456789/403248
Title: | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Authors: | Abou-Alfa, GK Yen, CJ Hsu, CH O'Donoghue, J Beylergil, V Ruan, ST Pandit-Taskar, N Gansukh, B Lyashchenko, SK Ma, J Wan, P Shao, YY Lin, ZZ Frenette, C O'Neil, B Schwartz, L Smith-Jones, PM Ohtomo, T Tanaka, T Morikawa, H Maki, Y Ohishi, N Chen, YC Agajanov, T Boisserie, F Di Laurenzio, L Lee, R Larson, SM Cheng, AL Carrasquilo, JA |
Issue Date: | 2017 | Source: | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Abstract: | Codrituzumab, a humanized antibody against glypican-3, is highly expressed in HCC. A phase I study evaluated the combination with sorafenib in HCC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/403248 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.